Modulating hydrogen-bond basicity within the context of protein-ligand binding: A case study with thrombin inhibitors that reveals a dominating role for desolvation

被引:6
作者
Nasief, Nader N. [1 ,2 ]
Said, Ahmed M. [1 ,3 ]
Hangauer, David [1 ]
机构
[1] SUNY Buffalo, Dept Chem, Buffalo, NY 14260 USA
[2] Natl Org Drug Control & Res NODCAR, Div Pharmaceut Chem, Giza, Egypt
[3] Helwan Univ, Fac Pharm, Dept Organ Pharmaceut Chem, Helwan, Egypt
关键词
Thrombin; Protein-ligand binding; Desolvation; Bioisosterism; Hydrogen bond; Cooperativity; Nonadditivity; B3LYP/6-31G*; STRUCTURE-BASED DESIGN; DRUG DESIGN; MOLECULAR RECOGNITION; SEMIEMPIRICAL METHODS; MEDICINAL CHEMISTS; FACTOR-XA; PHE-PRO; COOPERATIVITY; OPTIMIZATION; THERMODYNAMICS;
D O I
10.1016/j.ejmech.2016.09.038
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Understanding subtle aspects of hydrogen bonding is a challenging but crucial task to improve our ability to design ligands with high affinity for protein hosts. To gain a deeper understanding of these aspects, we investigated a series of thrombin inhibitors in which the basicity of the ligand's group that accepts an H-bond from Gly216 was modulated via bioisosterism; e.g., a C=O acceptor was made electron deficient or rich via bioisosteric replacements of the adjacent moiety. Although the ligand's binding affinity was anticipated to improve when the H-bond basicity is increased (due to stronger H-bonding with the protein), we herein present data that unexpectedly revealed an opposite trend. This trend was attributed to a dominating role played by desolvation in determining the relative binding affinity. For example, a decrease in the H-bond basicity reduces the desolvation penalty and, as experimentally observed, improves the binding affinity, given that the reduction in the desolvation penalty dominates the change in the net contribution of the ligand's interactions with the protein. The current study, therefore, reveals that desolvation can be a major underlying cause for the apparently counterintuitive structure-activity relationship (SAR) outcomes, and indicates that understanding this factor can improve our ability to predict binding affinity and to design more potent ligands. (C) 2016 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:975 / 991
页数:17
相关论文
共 49 条
  • [1] Hydrogen bond structural group constants
    Abraham, MH
    Platts, JA
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 2001, 66 (10) : 3484 - 3491
  • [2] HYDROGEN-BONDING .9. SOLUTE PROTON DONOR AND PROTON ACCEPTOR SCALES FOR USE IN DRUG DESIGN
    ABRAHAM, MH
    DUCE, PP
    PRIOR, DV
    BARRATT, DG
    MORRIS, JJ
    TAYLOR, PJ
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1989, (10): : 1355 - 1375
  • [3] HYDROGEN-BONDING .10. A SCALE OF SOLUTE HYDROGEN-BOND BASICITY USING LOG K VALUES FOR COMPLEXATION IN TETRACHLOROMETHANE
    ABRAHAM, MH
    GRELLIER, PL
    PRIOR, DV
    MORRIS, JJ
    TAYLOR, PJ
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1990, (04): : 521 - 529
  • [4] MOLECULAR RECOGNITION BY THROMBIN - ROLE OF THE SLOW-]FAST TRANSITION, SITE-SPECIFIC ION-BINDING ENERGETICS AND THERMODYNAMIC MAPPING OF STRUCTURAL COMPONENTS
    AYALA, YH
    DICERA, E
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1994, 235 (02) : 733 - 746
  • [5] ACTIVE SITE-DIRECTED SYNTHETIC THROMBIN INHIBITORS - SYNTHESIS, INVITRO AND INVIVO ACTIVITY PROFILE OF BMY 44621 AND ANALOGS - AN EXAMINATION OF THE ROLE OF THE AMINO GROUP IN THE D-PHE-PRO-ARG-H SERIES
    BALASUBRAMANIAN, N
    STLAURENT, DR
    FEDERICI, ME
    MEANWELL, NA
    WRIGHT, JJ
    SCHUMACHER, WA
    SEILER, SM
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (02) : 300 - 303
  • [6] DENSITY-FUNCTIONAL THERMOCHEMISTRY .3. THE ROLE OF EXACT EXCHANGE
    BECKE, AD
    [J]. JOURNAL OF CHEMICAL PHYSICS, 1993, 98 (07) : 5648 - 5652
  • [7] A Medicinal Chemist's Guide to Molecular Interactions
    Bissantz, Caterina
    Kuhn, Bernd
    Stahl, Martin
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (14) : 5061 - 5084
  • [8] Burger A., 1970, Medicinal chemistry, V3rd, P64
  • [9] CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
  • [10] Di Minno MND, 2013, CURR DRUG TARGETS, V14, P3